Clinical Trials Logo

Squamous Cell Carcinoma of Lung clinical trials

View clinical trials related to Squamous Cell Carcinoma of Lung.

Filter by:
  • None
  • Page 1

NCT ID: NCT05943795 Recruiting - Clinical trials for Squamous Cell Carcinoma of Lung

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Start date: July 14, 2023
Phase: Phase 3
Study type: Interventional

Main objectives: To evaluate the benefit of SI-B001+ docetaxel on overall survival (OS) of bidotaxel. To evaluate the benefit of SI-B001+ Docetaxel over Docetaxel's progression-free survival (PFS) based assessment. Secondary objectives: To evaluate the investigator-evaluated progression-free survival (PFS) benefit of SI-B001+ Docetaxel against docetaxel; To evaluate the difference of objective response rate (ORR), disease control rate (DCR) and duration of response (DOR) between SI-B001+ docetaxel and bidocetaxel. To evaluate the type, frequency and severity of adverse events (TEAE) and drug-related adverse events (TRAE) during treatment with SI-B001+ docetaxel in comparison with docetaxel. The pharmacokinetic (PK) characteristics of SI-B001 will be evaluated. The immunogenicity of SI-B001 will be evaluated. Subject quality of life.

NCT ID: NCT02009605 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of Lung

Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer.

NCT ID: NCT01969955 Recruiting - Clinical trials for Squamous Cell Carcinoma of Lung

Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer

Start date: September 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of nab-paclitaxel monotherapy in previously treated advanced or metastatic squamous lung cancer.